Topical antiseptics for chronic suppurative otitis media.

IF 8.8 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Karen Head, Lee Yee Chong, Mahmood F Bhutta, Jessica Daw, Tamara Veselinović, Peter S Morris, Shyan Vijayasekaran, Anne Gm Schilder, Christopher G Brennan-Jones
{"title":"Topical antiseptics for chronic suppurative otitis media.","authors":"Karen Head, Lee Yee Chong, Mahmood F Bhutta, Jessica Daw, Tamara Veselinović, Peter S Morris, Shyan Vijayasekaran, Anne Gm Schilder, Christopher G Brennan-Jones","doi":"10.1002/14651858.CD013055.pub3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic suppurative otitis media (CSOM), sometimes referred to as chronic otitis media (COM), is a chronic inflammation and often polymicrobial infection of the middle ear and mastoid cavity, characterised by ear discharge (otorrhoea) through a perforated tympanic membrane. The predominant symptoms of CSOM are ear discharge and hearing loss. Topical antiseptics, a possible treatment for CSOM, inhibit the micro-organisms that may be responsible for the infection. Antiseptics can be used alone or in addition to other treatments for CSOM, such as antibiotics or ear cleaning (aural toileting). However, the effects of topical antiseptics for CSOM remain unclear. This is an update of a review last published in 2020, with one new study added. It is one of a suite of seven Cochrane reviews evaluating the effects of non-surgical interventions for CSOM.</p><p><strong>Objectives: </strong>To assess the effects of topical antiseptics for people with CSOM.</p><p><strong>Search methods: </strong>We searched the Cochrane ENT Register, CENTRAL, Ovid MEDLINE, Ovid Embase, and five other databases. We also searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. The date of the latest search was 15 June 2022.</p><p><strong>Selection criteria: </strong>We included randomised controlled trials (RCTs) with at least a one-week follow-up involving participants (adults and children) who had chronic ear discharge of unknown cause or CSOM, where the ear discharge had continued for more than two weeks. The interventions were any single, or combination of, topical antiseptic agent of any class, applied directly into the ear canal as ear drops, powders, or irrigations, or as part of an aural toileting procedure. The two main comparisons were topical antiseptics (a) compared to placebo or no intervention, and (b) compared to another topical antiseptic (e.g. topical antiseptic A versus topical antiseptic B). Within each comparison, we separated studies into (a) those in which both groups of participants had received aural toileting in addition to the topical antiseptics, and those where neither group had received aural toileting, and (b) those in which both groups had received some other concomitant treatment (such as antibiotics) and those with no such concomitant treatment.</p><p><strong>Data collection and analysis: </strong>We used standard Cochrane methodological procedures. Our primary outcomes were resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not), measured at between one week and up to two weeks, two weeks to up to four weeks, and after four weeks; health-related quality of life using a validated instrument; ear pain (otalgia) or discomfort or local irritation. Secondary outcomes were hearing, serious complications, and ototoxicity. We used GRADE to assess the certainty of the evidence for each outcome.</p><p><strong>Main results: </strong>We found one new study (32 participants) in this update, for a total of six included studies with 435 participants (over four studies), plus 222 ears that could not be accounted for in participant numbers (in two studies). Four studies compared topical antiseptics with no treatment or placebo, and two studies compared two different topical antiseptics (boric acid versus acetic acid, and boric acid versus hydrogen peroxide). The two core comparisons of interest are reported below; other comparisons are described in the Results section of the review. No study measured health-related quality of life or ear pain. 1. Topical antiseptic versus placebo or no treatment Three studies (297 participants plus 174 ears) compared topical antiseptics with no treatment. Evidence from one study (unclear number of participants, 174 ears) is very uncertain about the effect of a single application of povidone iodine in hydroxypropyl methyl-cellulose (HPMC) on resolution of ear discharge at one week compared to HPMC alone; however, these results were only provided by ear (rather than by participant) and therefore could not be used quantitatively (very low-certainty evidence). One study (254 children; cluster-RCT) found that boric acid in alcohol ear drops with dry mopping may help resolution of ear discharge after four weeks compared with dry mopping alone, but the evidence is very uncertain (risk ratio (RR) 1.73, 95% confidence interval (CI) 1.21 to 2.47; 180 participants; very low-certainty evidence). We made adjustments to the data to account for the intracluster correlation. This study narratively described no clear differences in suspected ototoxicity or hearing outcomes between study arms, but the evidence is very uncertain (very low-certainty evidence). Evidence from one study (43 children; 58 ears) is very uncertain about the effect of antiseptics on serious complications. The study reported one case of mastoiditis and one of meningitis with focal encephalitis; however, it was unclear whether these were detected pre-randomisation or during/after treatment. 2. Topical antiseptics versus no treatment/placebo, where both study arms received systemic antibiotics One study (32 participants) compared topical povidone iodine with placebo (saline) in conjunction with oral amoxicillin and dry mopping. Topical povidone iodine with oral amoxicillin and dry mopping may increase resolution of ear discharge at one to two weeks (RR 3.25, 95% CI 1.35 to 7.84; 32 participants; low-certainty evidence). The study narratively reported no ototoxicity in the topical antiseptic arm; however, this was unclear for the placebo group, so we do not know if povidone iodine increases suspected ototoxicity (low-certainty evidence). The study did not assess resolution of ear discharge after four weeks, hearing, or serious complications.</p><p><strong>Authors' conclusions: </strong>We are very uncertain about the effect of topical antiseptics on improving resolution of ear discharge in people with CSOM given the low and very low certainty of the evidence, which was mostly due to risk of bias and imprecision. However, there is some evidence suggesting that boric acid in alcohol ear drops with dry mopping may help resolution of ear discharge compared with dry mopping alone, and that topical povidone iodine may be more effective than placebo (where both arms used systemic beta-lactam antibiotics and dry mopping). There is insufficient evidence to draw any conclusions about harmful effects. Limitations of the review include lack of recency in data, and limited information on certain population groups or interventions.</p>","PeriodicalId":10473,"journal":{"name":"Cochrane Database of Systematic Reviews","volume":"6 ","pages":"CD013055"},"PeriodicalIF":8.8000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146031/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Database of Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/14651858.CD013055.pub3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic suppurative otitis media (CSOM), sometimes referred to as chronic otitis media (COM), is a chronic inflammation and often polymicrobial infection of the middle ear and mastoid cavity, characterised by ear discharge (otorrhoea) through a perforated tympanic membrane. The predominant symptoms of CSOM are ear discharge and hearing loss. Topical antiseptics, a possible treatment for CSOM, inhibit the micro-organisms that may be responsible for the infection. Antiseptics can be used alone or in addition to other treatments for CSOM, such as antibiotics or ear cleaning (aural toileting). However, the effects of topical antiseptics for CSOM remain unclear. This is an update of a review last published in 2020, with one new study added. It is one of a suite of seven Cochrane reviews evaluating the effects of non-surgical interventions for CSOM.

Objectives: To assess the effects of topical antiseptics for people with CSOM.

Search methods: We searched the Cochrane ENT Register, CENTRAL, Ovid MEDLINE, Ovid Embase, and five other databases. We also searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. The date of the latest search was 15 June 2022.

Selection criteria: We included randomised controlled trials (RCTs) with at least a one-week follow-up involving participants (adults and children) who had chronic ear discharge of unknown cause or CSOM, where the ear discharge had continued for more than two weeks. The interventions were any single, or combination of, topical antiseptic agent of any class, applied directly into the ear canal as ear drops, powders, or irrigations, or as part of an aural toileting procedure. The two main comparisons were topical antiseptics (a) compared to placebo or no intervention, and (b) compared to another topical antiseptic (e.g. topical antiseptic A versus topical antiseptic B). Within each comparison, we separated studies into (a) those in which both groups of participants had received aural toileting in addition to the topical antiseptics, and those where neither group had received aural toileting, and (b) those in which both groups had received some other concomitant treatment (such as antibiotics) and those with no such concomitant treatment.

Data collection and analysis: We used standard Cochrane methodological procedures. Our primary outcomes were resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not), measured at between one week and up to two weeks, two weeks to up to four weeks, and after four weeks; health-related quality of life using a validated instrument; ear pain (otalgia) or discomfort or local irritation. Secondary outcomes were hearing, serious complications, and ototoxicity. We used GRADE to assess the certainty of the evidence for each outcome.

Main results: We found one new study (32 participants) in this update, for a total of six included studies with 435 participants (over four studies), plus 222 ears that could not be accounted for in participant numbers (in two studies). Four studies compared topical antiseptics with no treatment or placebo, and two studies compared two different topical antiseptics (boric acid versus acetic acid, and boric acid versus hydrogen peroxide). The two core comparisons of interest are reported below; other comparisons are described in the Results section of the review. No study measured health-related quality of life or ear pain. 1. Topical antiseptic versus placebo or no treatment Three studies (297 participants plus 174 ears) compared topical antiseptics with no treatment. Evidence from one study (unclear number of participants, 174 ears) is very uncertain about the effect of a single application of povidone iodine in hydroxypropyl methyl-cellulose (HPMC) on resolution of ear discharge at one week compared to HPMC alone; however, these results were only provided by ear (rather than by participant) and therefore could not be used quantitatively (very low-certainty evidence). One study (254 children; cluster-RCT) found that boric acid in alcohol ear drops with dry mopping may help resolution of ear discharge after four weeks compared with dry mopping alone, but the evidence is very uncertain (risk ratio (RR) 1.73, 95% confidence interval (CI) 1.21 to 2.47; 180 participants; very low-certainty evidence). We made adjustments to the data to account for the intracluster correlation. This study narratively described no clear differences in suspected ototoxicity or hearing outcomes between study arms, but the evidence is very uncertain (very low-certainty evidence). Evidence from one study (43 children; 58 ears) is very uncertain about the effect of antiseptics on serious complications. The study reported one case of mastoiditis and one of meningitis with focal encephalitis; however, it was unclear whether these were detected pre-randomisation or during/after treatment. 2. Topical antiseptics versus no treatment/placebo, where both study arms received systemic antibiotics One study (32 participants) compared topical povidone iodine with placebo (saline) in conjunction with oral amoxicillin and dry mopping. Topical povidone iodine with oral amoxicillin and dry mopping may increase resolution of ear discharge at one to two weeks (RR 3.25, 95% CI 1.35 to 7.84; 32 participants; low-certainty evidence). The study narratively reported no ototoxicity in the topical antiseptic arm; however, this was unclear for the placebo group, so we do not know if povidone iodine increases suspected ototoxicity (low-certainty evidence). The study did not assess resolution of ear discharge after four weeks, hearing, or serious complications.

Authors' conclusions: We are very uncertain about the effect of topical antiseptics on improving resolution of ear discharge in people with CSOM given the low and very low certainty of the evidence, which was mostly due to risk of bias and imprecision. However, there is some evidence suggesting that boric acid in alcohol ear drops with dry mopping may help resolution of ear discharge compared with dry mopping alone, and that topical povidone iodine may be more effective than placebo (where both arms used systemic beta-lactam antibiotics and dry mopping). There is insufficient evidence to draw any conclusions about harmful effects. Limitations of the review include lack of recency in data, and limited information on certain population groups or interventions.

慢性化脓性中耳炎的局部防腐剂。
背景:慢性化脓性中耳炎(CSOM),有时也被称为慢性中耳炎(COM),是中耳和乳突腔的一种慢性炎症和多微生物感染,其特征是通过穿孔的鼓膜漏耳(耳漏)。CSOM的主要症状是耳塞和听力丧失。局部杀菌剂,一种可能的治疗CSOM,抑制微生物,可能负责感染。抗菌剂可以单独使用,也可以与其他治疗方法一起使用,如抗生素或耳清洁(耳如厕)。然而,局部杀菌剂对CSOM的影响尚不清楚。这是对2020年发表的一篇综述的更新,其中增加了一项新研究。这是Cochrane评估非手术干预对CSOM影响的七篇综述之一。目的:评价外用杀菌剂对慢性som患者的治疗效果。检索方法:检索Cochrane ENT Register、CENTRAL、Ovid MEDLINE、Ovid Embase等5个数据库。我们还检索了ClinicalTrials.gov和世界卫生组织国际临床试验注册平台。最近一次搜索的日期是2022年6月15日。选择标准:我们纳入了随机对照试验(rct),随访至少一周,受试者(成人和儿童)患有不明原因的慢性耳部分泌物或CSOM,耳部分泌物持续超过两周。干预措施是任何一类局部消毒剂的任何单一或组合,直接应用于耳道,作为耳滴剂,粉末或冲洗,或作为耳如厕程序的一部分。两个主要的比较是局部防腐剂(a)与安慰剂或无干预的比较,以及(b)与另一种局部防腐剂(例如局部防腐剂a与局部防腐剂b)的比较。在每次比较中,我们将研究分为(a)两组参与者在使用局部防腐剂的同时还接受了耳如厕,以及两组都没有接受耳如厕的研究,以及(b)两组参与者都接受了其他一些伴随治疗(如抗生素)和未接受此类伴随治疗的研究。资料收集和分析:我们使用标准的Cochrane方法程序。我们的主要结果是耳部分泌物或“干耳”的消退(无论耳镜检查是否证实),在一周至两周、两周至四周和四周后测量;使用经过验证的仪器检测与健康有关的生活质量;耳痛(耳痛)或不适或局部刺激。次要结果是听力、严重并发症和耳毒性。我们使用GRADE来评估每个结果证据的确定性。主要结果:我们在本次更新中发现了一项新研究(32名参与者),总共纳入了6项研究,共有435名参与者(超过4项研究),加上222名参与者(在2项研究中)无法解释。四项研究比较了未治疗或安慰剂的局部防腐剂,两项研究比较了两种不同的局部防腐剂(硼酸与乙酸,硼酸与过氧化氢)。下面报告了两项核心比较;其他比较在综述的“结果”部分进行了描述。没有研究测量与健康相关的生活质量或耳痛。1. 三项研究(297名参与者加174只耳朵)比较了局部抗菌剂和不治疗。一项研究(参与者人数不清楚,174只耳朵)的证据非常不确定羟丙基甲基纤维素(HPMC)中单次应用聚维酮碘与单独使用HPMC相比,在一周内解决耳部排出问题的效果;然而,这些结果仅由耳朵(而不是参与者)提供,因此不能定量使用(非常低确定性的证据)。一项研究(254名儿童;聚类随机对照试验发现,与单独干拖地相比,含硼酸的酒精滴耳液在4周后可能有助于解决耳漏问题,但证据非常不确定(风险比(RR) 1.73, 95%可信区间(CI) 1.21 ~ 2.47;180名参与者;非常低确定性证据)。我们对数据进行了调整,以解释集群内的相关性。该研究叙述了两组研究之间在疑似耳毒性或听力结果方面没有明显差异,但证据非常不确定(非常低确定性的证据)。来自一项研究的证据(43名儿童;(58年)对于防腐剂对严重并发症的影响是非常不确定的。本研究报告乳突炎1例,脑膜炎伴局灶性脑炎1例;然而,尚不清楚这些是否在随机化前或治疗期间/之后检测到。2. 一项研究(32名参与者)比较了外用聚维酮碘与安慰剂(生理盐水)联合口服阿莫西林和干拖地。局部用聚维酮碘联合口服阿莫西林和干擦可在1 - 2周内提高耳部分泌物的分辨率(RR 3.25, 95% CI 1.35 - 7.84;32个参与者;确定性的证据)。该研究叙述性地报道了局部抗菌组无耳毒性;然而,安慰剂组的情况尚不清楚,因此我们不知道聚维酮碘是否会增加疑似耳毒性(低确定性证据)。该研究没有评估四周后耳部分泌物的消退、听力或严重并发症。作者的结论:鉴于证据的低确定性和非常低的确定性,我们非常不确定外用杀菌剂对改善CSOM患者耳部分泌物溶解的作用,这主要是由于存在偏倚和不精确的风险。然而,有一些证据表明,酒精滴耳液中的硼酸与干拖地相比,可能有助于解决耳漏问题,并且局部聚维酮碘可能比安慰剂更有效(两组都使用全身-内酰胺抗生素和干拖地)。没有足够的证据得出有害影响的结论。该审查的局限性包括数据缺乏近时性,以及关于某些人群或干预措施的信息有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.60
自引率
2.40%
发文量
173
审稿时长
1-2 weeks
期刊介绍: The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信